Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

Diabetes Care. 2017 Jun;40(6):808. doi: 10.2337/dc17-er06. Epub 2017 Apr 18.
No abstract available

Publication types

  • Published Erratum